British researchers have found that many fixed-dose drug combinations (FDCs) in India lack central regulatory approval despite concerns over the safety and efficacy of such combinations. A study led by Queen Mary University of London, revealed that these FDCs are being sold in substantial numbers in India.<\/p>\n
In 2012, the Parliamentary Standing Committee on Health & Family Welfare reported that a very large number of FDCs had been licensed by state drug authorities without approval by the Central Drugs Standard Control Organisation (CDSCO).<\/p>\n
Patricia McGettigan who led the study at Queen Mary University of London, is of the opinion,<\/p>\n
“India needs to ban the sale and manufacturing of fixed-dose drug combinations not approved by the CDSCO — beginning with those which include drugs banned or unapproved internationally and, therefore, most likely to be harmful.”<\/strong><\/em><\/p>\nFactsheet<\/h2>\n